Crimean-Congo Haemorrhagic Fever Virus Nucleocapsid Antigen, Recombinant

Rif. 3D-CP6494-R

Informazioni sul prodotto

• Nome: Crimean-Congo Haemorrhagic Fever Virus Nucleocapsid Antigen, Recombinant
• Marchio: Biosynth
• Descrizione: Crimean-Congo Haemorrhagic Fever Virus is a tick-borne virus that causes Crimean-Congo Haemorrhagic Fever (CCHF), a serious disease that can have a case fatality rate of up to 40% during outbreaks. The virus is an RNA virus from the Nairoviridae family and is transmitted mainly through bites from infected ticks (especially Hyalomma species) or through contact with blood or tissues from infected animals or people. It is found across Africa, the Balkans, the Middle East, and parts of Asia. Symptoms can include fever, muscle aches, dizziness, neck pain, and backache and it can progress to internal and external bleeding, liver failure, and shock. Currently there is no vaccine to combat this disease, or an antiviral treatment that has been officially approved.The Crimean-Congo Haemorrhagic Fever Virus nucleocapsid antigen is a structural protein of the virus. It wraps around the viral RNA genome to form the nucleocapsid, protecting the RNA and helping the virus replicate inside host cells. It's highly abundant, highly conserved, and produced early during infection. This protein is therefore a prime target for use in the development of new diagnostic assays for Crimean-Congo Haemorrhagic Fever Virus detection. The fact that the nucleocapsid protein is immunogenic it can also be used in vaccine research.Cymit Quimica's recombinant Crimean-Congo Haemorrhagic Fever Virus antigen is the full-length nucleocapsid protein from strain Nigeria/IbAr10200/1970 expressed in E. coli and containing a His-tag at the C-terminus. This antigen is potentially suitable for development of serological assays, such as ChLIA, ELISA and lateral flow, to detect the presence of antibodies to CCHF virus in patient samples.